A meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on June 7, 2026, with the following interim recommendation made:

• Bisacodyl, when sold in strengths of 10 mg or less per rectal dosage unit/suppository, in package sizes containing no more than 70 mg of bisacodyl, be granted Unscheduled Status.

Any objections to this interim recommendation must be received by the NAPRA office by end of day July 15, 2026. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.